Results 141 to 150 of about 7,633 (200)

Impact of Oral Mesalamine on Clinical Remission and Mucosal Response in Mild to Moderate Ulcerative Colitis: A Prospective Observational Study. [PDF]

open access: yesCureus
Nabeel L   +9 more
europepmc   +1 more source

Mesalamine-Associated Thrombocytopenia

open access: yesAmerican Journal of Gastroenterology, 1999
We describe a case of a 25-yr-old woman with ulcerative colitis who developed marked thrombocytopenia during treatment and upon rechallenge with oral mesalamine. In contrast to its parent drug, sulfasalazine, which has often been reported to cause serious blood disorders, particularly agranulocytosis, mesalamine has rately been implicated as a cause of
Farrell, R. J.   +3 more
core   +5 more sources

Attitudes to Mesalamine Questionnaire: A Novel Tool to Predict Mesalamine Nonadherence in Patients with IBD

open access: yesAmerican Journal of Gastroenterology, 2014
Poor adherence to mesalamine is common and driven by a combination of lifestyle and behavioral factors, as well as health beliefs. We sought to develop a valid tool to identify barriers to patient adherence and predict those at risk for future nonadherence.A 10-item survey was developed from patient-reported barriers to adherence.
Moss, Alan   +7 more
openaire   +5 more sources

Effectiveness of Mesalamine and Propolis in Experimental Colitis

open access: yesAdvances in Therapy, 2007
PubMedID: 18029336This study was conducted to investigate the effects of propolis and mesalamine on experimental colitis in rats. Distal colitis was induced in rats by intracolonic instillation of 2 mL of 4% acetic acid.
Nuray Sahinler, Esin Atik
exaly   +2 more sources

Mesalamine

Hospital Pharmacy, 2007
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada   +2 more
openaire   +1 more source

Asacol (Mesalamine)

Gastroenterology Nursing, 1992
Asacol (mesalamine) is a delayed release pH-sensitive, polymer-coated, oral preparation of 5-ASA which releases the drug in the terminal ileum and colon for the treatment of mildly to moderately active ulcerative colitis. Treatment modalities using Asacol appear to be an alternative for sulfasalazine-sensitive patients as well as potential first-line ...
openaire   +2 more sources

Pentasa (Mesalamine)

Gastroenterology Nursing, 1993
Pentasa (mesalamine) is a newly released oral 5-aminosalicylic acid capsule marketed by Marion Merrel Dow Inc., for the induction of remission and for the treatment of mildly to moderately active ulcerative colitis. Ulcerative colitis is a chronic inflammatory disease and the most common form of inflammatory bowel disease, which is a debilitating and ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy